PBAC's latest decision on Eribulin: Recommended with restriction (2016). Considered for Advanced or metastatic liposarcoma in patients who have failed prior chemotherapy, including an anthracycline.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Redacted
commercial-in-confidence
Submissions
1
first 2016
Submissions
1
2016 → 2016
Eligible population
Adults aged 18 years or older with advanced (unresectable and/or metastatic) liposarcoma (myxoid, pleomorphic, dedifferentiated, or round cell subtypes) who have received prior chemotherapy including an anthracycline, with WHO ECOG performance status of 2 or less.
Therapy area
Oncology
Line of therapy
Second-line
Evidence base
RCT
Primary endpoint
OS
Pivotal trial size
452 patients
Key trials
Study 309, van Oosterom 2002
Comparator
dacarbazine
Economic model
CUA
ICER note
ICER values are redacted (denoted as '''''' in the price schedule).